Premium
Bi‐labelled antibody and Bi‐labelled streptavidin. Comparison of targeting efficacy of a lymphoma cell line in vitro
Author(s) -
Henriksen Gjermund,
Funderud Steinar,
Hoff Per
Publication year - 1997
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/(sici)1099-1344(199712)39:12<1039::aid-jlcr41>3.0.co;2-x
Subject(s) - streptavidin , biotinylation , chemistry , in vitro , antibody , chelation , cell culture , microbiology and biotechnology , monoclonal antibody , biochemistry , biotin , immunology , organic chemistry , genetics , biology
An anti‐lymphoma antibody (HH‐1) and streptavidin were conjugated with the chelator CHX‐A DTPA and subsequently labelled with 205,206 Bi. The immunoreactivity of the antibody to the target antigen and the binding ability of streptavidin to antigen‐bound biotinylated HH‐1 were then investigated at different degrees of chelator content. Streptavidin was shown to be more tolerant than HH‐1 towards the chelator modification. While the binding reactivity of HH‐1 decreased to 60% at an average of 3.5 chelators per molecule, the 60% level was obtained at an average of 6.5 chelators per streptavidin molecule. Streptavidin may therefore possibly be used to obtain 212,213 Bi‐labelled compounds for α‐particle radiotherapy with higher specific activity. © 1997 John Wiley & Sons, Ltd.